Filing Flows

Filing Flows › 8-K events › uniQure N.V.

uniQure N.V.: regulation fd disclosure

Form 8-K filed Nov 2, 2026 · items 7.01, 8.01

FDA decisionsuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

What the filing says

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ~ FDA sets PDUFA target action date of May 1, 2027 ~

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

uniQure N.V. at a glance

Latest quarterQ3 2026
Revenue$5.2M
Revenue Y/Y+40%
Operating marginn/m
IndustryPharmaceutical Preparations

uniQure N.V., Q3 2026: revenue $5.2M (+40% year over year). The chart follows the revenue to costs, profit and cash.

uniQure N.V.: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.